Cardiovascular Summit TCTAP 2013 Symposium to Feature OrbusNeich's COMBO Dual Therapy Stent (TM)

HONG KONG, April 23, 2013 /PRNewswire/ -- OrbusNeich today announced that it will host a symposium featuring the COMBO Dual Therapy Stent at the Cardiovascular Summit TCTAP 2013 in Seoul, South Korea. The symposium, entitled "A New Dimension to Stent Therapy" will take place at 12:45 p.m. KST on Thursday, April 25, in the Coronary Arena, Level 1. The event will be chaired by Dr. Seung-Jung Park, of Asan Medical Center, Seoul, South Korea, and Dr. Mitchell Krucoff, of Duke University Medical Center, Durham, N.C.

Agenda

• Opening address – Dr. Seung-Jung Park
• Evaluating COMBO's Healing Profile -- The EGO COMBO Serial OCT Study -- Prof. Stephen W.L. Lee, Queen Mary Hospital, University of Hong Kong
• Q&A – Dr. Seung-Jung Park
• Dual Therapy Stent -- Is There a Need? -- Dr. Tiong Kiam Ong, Sarawak General Hospital, Malaysia
• Dual Therapy Stent -- Addressing the Unmet Needs of Balancing Bleeding & Ischemic Events -- The Clinical View -- Dr. Mitchell Krucoff
• Q&A and Closing Remarks -- Dr. Mitchell Krucoff

"We continue to see robust results for the COMBO Dual Therapy Stent showing that it achieves both durable (24 months) neointimal suppression in addition to excellent healing at early months," said Prof. Lee.

Dr. Park added, "Because the COMBO Stent limits neointimal proliferation while accelerating the healing process, it may provide interventional cardiologists with a safe and effective treatment option that will ultimately reduce our dependence on long-term dual antiplatelet therapy."

About the COMBO Dual Therapy Stent

The COMBO Dual Therapy Stent is the first dual therapy stent to both accelerate endothelial coverage and control neo-intimal proliferation through the combination of the proven pro-healing technology with an abluminal sirolimus drug elution delivered from a biodegradable polymer that achieves full and complete dissipation by 90 days.

OrbusNeich's patented endothelial progenitor cell (EPC) capture technology promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that captures EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Stent, as well as other stents and balloons marketed under the names of Azule™, R stent, Scoreflex™, Sapphire™, Sapphire II and Sapphire NC. Development stage products include the COMBO Dual Therapy Stent, the world's first dual therapy stent. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, mainland China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.

Follow OrbusNeich on Twitter at www.twitter.com/OrbusNeich, and learn more about the company and its innovative technology on OrbusNeich's YouTube Channel: http://www.youtube.com/user/OrbusNeichMedia.